Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Rusfertide in Patients with Polycythemia Vera
2021-004732-29Phase 3Active
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Mar 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polycythemia vera (PV) comparing Rusfertide with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving response (hematocrit control without phlebotomy eligibility). Started Mar 2022; status: active.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2021-004732-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004732-29.